777 related articles for article (PubMed ID: 17393458)
21. Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis.
Daleboudt GM; Broadbent E; Berger SP; Kaptein AA
Lupus; 2011 Mar; 20(3):290-8. PubMed ID: 21362752
[TBL] [Abstract][Full Text] [Related]
22. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
[TBL] [Abstract][Full Text] [Related]
23. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
24. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.
Camous L; Melander C; Vallet M; Squalli T; Knebelmann B; Noël LH; Fakhouri F
Am J Kidney Dis; 2008 Aug; 52(2):346-52. PubMed ID: 18572292
[TBL] [Abstract][Full Text] [Related]
25. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide.
Cunnane G; Chan OT; Cassafer G; Brindis S; Kaufman E; Yen TS; Daikh DI
Arthritis Rheum; 2004 May; 50(5):1539-48. PubMed ID: 15146424
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic options for resistant lupus nephritis.
Mok CC
Semin Arthritis Rheum; 2006 Oct; 36(2):71-81. PubMed ID: 16884971
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
[TBL] [Abstract][Full Text] [Related]
29. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
Pepper R; Griffith M; Kirwan C; Levy J; Taube D; Pusey C; Lightstone L; Cairns T
Nephrol Dial Transplant; 2009 Dec; 24(12):3717-23. PubMed ID: 19617257
[TBL] [Abstract][Full Text] [Related]
30. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
32. An open study of B lymphocyte depletion in systemic lupus erythematosus.
Leandro MJ; Edwards JC; Cambridge G; Ehrenstein MR; Isenberg DA
Arthritis Rheum; 2002 Oct; 46(10):2673-7. PubMed ID: 12384926
[TBL] [Abstract][Full Text] [Related]
33. Treatment and renal outcome of lupus nephritis: single center experience.
Go KW; Teo SM
Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
35. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
36. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
37. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era.
Stone JH; Millward CL; Olson JL; Amend WJ; Criswell LA
Arthritis Rheum; 1998 Apr; 41(4):678-86. PubMed ID: 9550477
[TBL] [Abstract][Full Text] [Related]
38. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
Kim YG; Kim HW; Cho YM; Oh JS; Nah SS; Lee CK; Yoo B
Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
[TBL] [Abstract][Full Text] [Related]
40. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Wang HY; Cui TG; Hou FF; Ni ZH; Chen XM; Lu FM; Xu FF; Yu XQ; Zhang FS; Zhao XZ; Zhao MH; Wang GB; Qian JQ; Cai GY; Zhu TY; Wang YH; Jiang ZP; Li YN; Mei CL; Zou WZ;
Lupus; 2008 Jul; 17(7):638-44. PubMed ID: 18625636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
